Aurinia names Charles Rowland as CEO
Mr. Rowland has more than 30 years of experience in pharmaceutical operations, strategic value creation as well as financial management. He served as the Vice President and Chief Financial Officer of ViroPharma Incorporated, an international biopharmaceutical company, until it was acquired by Shire plc in January 2014.
Prior to joining ViroPharma in 2008, Mr. Rowland held a number of leadership positions at several biotechnology and pharmaceutical companies, most recently as interim Co-Chief Executive Officer and Executive Vice President and Chief Financial Officer for Endo Pharmaceuticals Inc., a specialty pharmaceutical company with a primary focus in pain management, where he served from 2006 to 2008.
At Endo, Mr. Rowland drove the strategic planning process, including the design and implementation of the company's mid and long-term business and financial strategy.
Mr. Rowland previously held positions of increasing responsibility at Biovail Corporation, Breakaway Technologies, Inc., Pharmacia Corporation, Novartis AG and Bristol-Myers Squibb.
Mr. Rowland’s board experience includes companies such as BluePrint Medicines, Vitae Pharmaceuticals and Idenix Pharmaceuticals. Idenix was acquired by Merck in 2014. ■